Transforming Growth Factor Beta 1 (TGFB1) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Transforming Growth Factor Beta 1 (TGFB1) – Pipeline Review, H1 2018’, provides in depth analysis on Transforming Growth Factor Beta 1 (TGFB1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Ophthalmology, Respiratory, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders under development targeting Transforming Growth Factor Beta 1 (TGFB1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

– The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Acceleron Pharma Inc

AlfaSigma SpA

Ensol Biosciences Inc

Formation Biologics Inc

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Scholar Rock Inc

Sirnaomics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Transforming Growth Factor Beta 1 (TGFB1) Overview

Transforming Growth Factor Beta 1 (TGFB1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transforming Growth Factor Beta 1 (TGFB1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transforming Growth Factor Beta 1 (TGFB1) Companies Involved in Therapeutics Development

Acceleron Pharma Inc

AlfaSigma SpA

Ensol Biosciences Inc

Formation Biologics Inc

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Scholar Rock Inc

Sirnaomics Inc

Transforming Growth Factor Beta 1 (TGFB1) Drug Profiles

ACE-1332 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit TGF-Beta 1 for Osteoarthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVID-200 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Engedi-1000 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluorofenidone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1047 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1106 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGFB1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGFB1 for Oncology and Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulodexide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-089 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transforming Growth Factor Beta 1 (TGFB1) Dormant Products

Transforming Growth Factor Beta 1 (TGFB1) Discontinued Products

Transforming Growth Factor Beta 1 (TGFB1) Product Development Milestones

Featured News & Press Releases

Feb 17, 2018: AVID200 Program Featured in an Oral Presentation at the 5th Systemic Sclerosis World Congress and Received an Award for One of the Most Original Works Presented at the Congress

Feb 02, 2018: Formation Biologics Announces Award of $675,000 BioCanRx Grant to Support Development of AVID200

Dec 06, 2017: Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma

Oct 06, 2017: Sirnaomics Publishes Results Showing Dual Targeting of TGF-ß1 and COX-2 Reduces Human Skin Hypertrophic Scar through Activation of Fibroblast Apoptosis

Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis

Jun 15, 2017: Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, for Treatment of Liver Fibrosis

May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Jan 03, 2017: Haiyao Obtains Clinical Trial Approval for Fluorofenidone from General Administration of Pharmacy, China

Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFß1 Latent Complex

Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US

Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA

Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field

Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Acceleron Pharma Inc, H1 2018

Pipeline by AlfaSigma SpA, H1 2018

Pipeline by Ensol Biosciences Inc, H1 2018

Pipeline by Formation Biologics Inc, H1 2018

Pipeline by Genzyme Corp, H1 2018

Pipeline by Huabo Biopharm Co Ltd, H1 2018

Pipeline by Isarna Therapeutics GmbH, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Scholar Rock Inc, H1 2018

Pipeline by Sirnaomics Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports